Boston Institute of Biotechnology and BiBo Pharma Expansion
Boston Institute of Biotechnology, LLC (BIB), along with its sister company BiBo Pharma, has announced a bold new initiative to enhance their production capabilities. This groundbreaking investment highlights their commitment to becoming leaders in the global biologics manufacturing sector and meeting the ever-growing demand for high-quality biologics.
Major Expansion Plans
Building upon the successful launch of their innovative 30,000L stainless steel bioreactors, the two entities are set to significantly increase their total fermentation capacity by over 350,000 liters. This expansion is a strategic response to the robust global market demand for ultra-large-scale biologics production.
New Facilities and Production Lines
The upcoming facilities will be equipped with advanced mammalian cell culture production lines, featuring at least four 30,000L, two 15,000L, and one 5,000L (perfusion capable) bioreactors. This alone will add over 150,000 liters of working volume. In addition, microbial fermentation production lines will include three 30,000L, one 10,000L, and two 3,000L fermentors, resulting in an extra working volume of over 100,000 liters. Combined, these upgrades will significantly boost BIB's operational capacity.
Future Leadership in Biologics
By the end of 2025, BIB and BiBo Pharma are on track to secure exclusive global ownership of ultra-large-scale mammalian cell production lines. This positioning will likely establish them as the world's largest Contract Development and Manufacturing Organization (CDMO) specializing in microbial fermentation capacity for biologics.
Expanding Antibody-Drug Conjugate Production
In addition to their large-scale bioreactor capabilities, BIB and BiBo Pharma will broaden their scope in Antibody-Drug Conjugates (ADC) manufacturing. This expansion will include new conjugation workshops, with reactors varying from 5 liters to 500 liters, and an impressive annual design capacity exceeding 600 kg.
Innovative Production Technologies
Leveraging their proprietary PanFlex-Engineering system, BIB has revolutionized the biologics manufacturing landscape. The firm's advanced production technologies are aimed at building a million-liter production base, which will be a cornerstone of their future plans.
Commitment to Innovation
The companies are dedicated to leading the fourth wave of biologics manufacturing by drastically cutting costs and improving production efficiency. Their strategic application of advanced process technologies has enabled a dramatic reduction in production costs, bringing it down to as low as $10 per gram for antibodies.
About BIB and BiBo Pharma
Founded in 2014, BIB and BiBo Pharma operate as global sister companies dedicated to full-spectrum global Contract Development and Manufacturing Organization (CDMO) services. With extensive R&D facilities and GMP factories, they provide clients with access to cutting-edge technologies across multiple disciplines, including microbial fermentation, mammalian cell culture, gene therapy, and ADCs.
Frequently Asked Questions
What is the focus of BIB and BiBo Pharma's expansion?
Their expansion primarily focuses on increasing the production capacity of biologics, specifically through the use of large-scale bioreactors and ADC manufacturing capabilities.
How much will BIB and BiBo Pharma increase their capacity?
They plan to increase their total fermentation capacity by over 350,000 liters to meet global market demands.
What new technologies are being utilized in their production?
BIB is leveraging its proprietary PanFlex-Engineering system along with other advanced production technologies designed to enhance efficiency and reduce costs.
When is the expansion expected to be complete?
The expansion is expected to be completed by the end of 2025, marking significant growth in their biologics manufacturing capabilities.
What is the significance of their ADC manufacturing capabilities?
The expansion of ADC manufacturing capabilities will allow for increased production flexibility and capacity, further enhancing their service offerings in the biopharmaceutical space.
